Founder, Partner, Chief Operations Officer

As a co-founder of PES, Dr. Lyng is responsible for the oversight of all PES research collaborations.  Additionally, he works closely with PES clients to ensure proper design and utilization of EdQ™ management.  Dr. Lyng’s scientific expertise lies in translational research spanning the areas of inflammatory disease, cancer supportive care, oncology, and diseases of the central nervous system.  Dr. Lyng received his Ph.D. in Biomedical Sciences from the University at Albany School of Public Health and his B.S. in Neuroscience from St. Lawrence University.  In addition to his role at PES, Dr. Lyng is the Chief Operating Officer at Biomodels, LLC where he is responsible for the oversight of their preclinical/translation research programs.

Founder, Partner, Chief Scientific Officer

Dr. Sonis is a senior academic and research scientist who holds appointments at the Harvard School of Dental Medicine (HSDM), the Dana-Farber Cancer Institute (DFCI), and Brigham and Women’s Hospital (BWH). After receiving his DMD from Tufts, Dr. Sonis completed a combined doctorate and specialty training program at Harvard and was a Knox Fellow at Oxford (UK) where he studied tumor immunology. In addition to his academic appointments, Dr. Sonis is the Chief Scientific Officer of Biomodels, LLC; Co-Founder and Chief Scientific Advisor of Inform Genomics; Past president of TRIAD Burden of Illness Studies, a not-for-profit company focusing on the adverse health and economic outcomes of cancer toxicities.

Founder, Managing Partner

Mr. Lichtman has been the Managing Partner at Biomodels since 2012. Following sales and marketing positions at Abbott, J+J and Bayer, He recognized opportunities presented by advances in medical technology and founded an in-vitro diagnostic instrumentation company when diagnostics was in its infancy and its distribution was an unsophisticated part of hospital supply. Additionally, Mr. Lichtman saw drug discovery as synergistic with diagnostics and founded a contract research organization. The success of both companies reflects Mr. Lichtman’s commitment to innovation and excellence. He brings his management skills as a CEO and his commitment to translational research to Biomodels to amplify the corporate philosophy of an employee-centric culture.

Founder, Partner, Chief Financial Officer

As a co-founder of Primary Endpoint Solutions, Ms. Trewin serves as its Chief Financial Officer. Ms. Trewin also provides leadership at Biomodels as its Chief Financial Officer, bringing her extensive experience with pre-clinical research and medical diagnostic instrumentation companies, including Inter-Medico, NoAb BioDiscoveries, and LabOne. In addition, she has held public accounting and other industry positions at KPMG, Ernst Young and Avery Dennison. Ms. Trewin holds a Bachelor of Commerce degree from the University of Toronto and is a member of Canadian Institute of Chartered Accounts and holds a CPA, CA designation.

Alessandro Villa - PES Clinical

Clinical Indication Expert

Dr. Villa is a clinical indication expert in oral and maxillofacial diseases, who joined PES in 2016. In addition to his PES role, Dr. Alessandro Villa is the Chief of Oral Medicine and Director of Oral Oncology at the University of California San Francisco where he also serves as program director for the Oral Medicine Residency program. Previously, he was an associate surgeon at Brigham and Women’s Hospital and Dana-Farber Cancer Institute and served as the Program Director for the Oral Medicine Residency Program at Harvard University.

After completing his dental education at the University of Milano, Italy, he obtained his Master of Public Health (AT Still University) and PhD (University of Sassari, Italy). Following a post-doctoral fellowship at the National Cancer Institute, where he studied oral HPV prevalence and methods of early oral cancer detection, Dr. Villa completed the Harvard Oral Medicine Residency program at Brigham and Women’s Hospital. Dr. Villa’s research interests are focused primarily on oral complications of cancer treatment, including mucositis. Dr. Villa has published extensively on topics related to cancer regimen toxicities, the epidemiology of oral and oropharyngeal cancer and disparities in treatment outcomes. He is an established clinical trialist.

Jesus Mena - PES Clinical

Biobanking Director

Dr. Mena serves as the Biobanking Director for PES. As the principal supervisor of the Biobanking facility, he oversees sample acquisition, maintenance, and storage. He also performs oversight of internal audits, records management, and compliance with internal and external regulatory considerations. In addition to his role at PES, Dr. Mena is also Regulatory Compliance Manager and Scientist II at Biomodels, PES’ sister company. Dr. Mena received his Ph.D. from the University of Wisconsin-Madison and his B.S. in Biology and Psychology from Tufts University.

Senior Project Manager

Amanda graduated from the University of Massachusetts Amherst with a Bachelor of Science in Public Health and a minor in Psychology. She joined Primary Endpoint Solutions as a Clinical Research Associate and is now a Senior Clinical Project Manager. In addition to Project Management, Amanda works with the Biobank Manager to ensure the integrity of samples stored at PES.

Charlotte Dowden - PES Project Manager

Project Manager

Charlotte Dowden joined Primary Endpoint Solutions in 2018 as a clinical research associate and is currently a Project Manager. Previously, she worked in the Nock Lab at Harvard University researching neurodegenerative diseases under Dr. Marie-Christine Nizzi and Dr. Matthew Nock. Additionally, Charlotte managed the Autism Speaks, Autism Treatment Network research at Massachusetts General Hospital. She received her Bachelor of Science from the University of Massachusetts Amherst in psychology with a concentration in neuroscience.

Sandford Katz - PES Clinical

Dr. Katz partners with PES to provide our clients with radiation therapy quality assurance (RTQA) services as well support to Data Safety and Monitoring Boards (DSMB). In addition to his role with PES, Dr. Katz is a radiation oncologist in private practice at the Willis-Knighton Cancer and Proton Therapy Center, with academic appointments at the Louisiana State University School of Medicine in the Departments of Otolaryngology-Head and Neck Surgery, Oral and Maxillofacial Surgery, and Radiology. Dr. Katz received his MD from the University of Maryland, completed his clinical training at Georgetown University, and is a Fellow of the American College of Radiation Oncology. With a special interest in reducing cancer treatment-related toxicity, Dr. Katz is active in the development and clinical application of both technical as well as novel pharmacologic interventions. Dr. Katz has considerable clinical trial experience, serving in roles as a primary investigator as well as a clinical consultant on protocol design, quality assurance, and data safety monitoring.

Juan Fernande Martinez PhD - PES Clinical

Dr. Fernández-Martínez is a principle collaborator and analyst for genomic data, machine learning, and optimization. Juan joined the company in 2015. Dr. Fernàndez-Martìnez received his Ph.D. in mining engineering from the University of Oviedo (Spain) in 1994, and was previously trained as a petroleum engineer in France (Ècole Nationale du Pètrole et des Moteurs, Paris, 1988) and England (Imperial College, Royal School of Mines, London, 1989). After years of working as a computing software engineer in France, he joined the Mathematics Department of Oviedo University in 1994 and where he holds the position as full professor in applied mathematics since 2018. During 2008-2010 he was a visiting and research professor at UC Berkeley-Lawrence Berkeley Laboratories and Stanford University. His areas of expertise include inverse problems, uncertainty analysis of very complex systems, feature selection and model reduction techniques, cooperative global optimization methods, with application in oil and gas, biometry, biomedicine and finance. In the area of biomedicine he is interested in simplifying the complexity of the genome for medical diagnosis and de novo drug design and drug repositioning and has published and lectured extensively in this area.

Distance Learning Director

Dr. Diehl is a distance education and multimedia expert who has provided direction to PES since the company’s founding. In his PES role, Will optimizes the design, content and enablement of our training activities. In addition to his work with PES, Will is a highly sought after consultant in the corporate, higher education, healthcare, and government sectors. He is also an assistant professor and coordinator of online graduate programs in the Lifelong Learning and Adult Education program in the College of Education at Penn State University. He serves as Associate Editor for The American Journal of Distance Education, is the Director of The American Center for the Study of Distance Education, and co-editor of the Handbook of Distance Education (4th edition). Will’s distance learning expertise is supplemented by his significant and diverse experiences in education and technology.